GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Importance: Metabolic dysfunction-associated steatotic liver disease (MASLD) is an increasing cause of cirrhosis. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are effective in improving liver inflammation in patients with MASLD. Objective: To determine whether use of GLP-1 RAs is associated with lower risk of developing cirrhosis and its complications, including decompensation and hepatocellular cancer (HCC), among patients with MASLD. Design, Setting, and Participants: This retrospective cohort study with an active comparator, new-user design used data from the national Veterans Health Administration Corporate Data Warehouse and Central Cancer Registry. Patients with MASLD and diabetes who were seen at 130 Veterans Health Administration hospitals and associated ambulatory clinics and who initiated either a GLP-1 RA or dipeptidyl peptidase 4 inhibitor (DPP-4i) between January 1, 2006, and June 30, 2022, were included. Patients were followed up from baseline until one of the study outcomes or the end of the study period (December 31, 2022), whichever came first. Exposures: Each GLP-1 RA new user was propensity score matched in 1:1 ratio to a patient who initiated a DPP-4i during the same month. Separate analyses were conducted among patients without and with cirrhosis at baseline. Main Outcomes and Measures: For patients without cirrhosis, the primary outcome was progression to cirrhosis defined by validated diagnoses codes or a noninvasive marker of liver fibrosis, and secondary outcomes were cirrhosis complications defined both as a composite and individual complications, including decompensation, HCC, or liver transplant, and all-cause mortality. For patients with cirrhosis, the primary outcome was a composite outcome of cirrhosis complications, and secondary outcomes were decompensation, HCC, and all-cause mortality. Results: Of 16 058 patients who initiated GLP-1 RAs, 14 606 did not have cirrhosis (mean [SD] age, 60.56 [10.31] years; 13 015 [89.1%] male), and 1452 had cirrhosis (mean [SD] age, 66.99 [7.09] years; 1360 [93.7%] male) at baseline. These patients were matched to an equal number of patients who initiated a DPP-4i. In patients without cirrhosis, GLP-1 RA use, compared with DPP-4i use, was associated with a lower risk of cirrhosis (9.98 vs 11.10 events per 1000 person-years; hazard ratio [HR], 0.86; 95% CI, 0.75-0.98). Similar results were seen for the secondary outcomes. GLP-1 RA use, compared with DPP-4i use, was associated with a lower risk of the composite outcome of cirrhosis complications (1.89 vs 2.55 events per 1000 person-years; HR, 0.78; 95% CI, 0.59-1.04) and mortality (21.77 vs 24.43 events per 1000 person-years; HR, 0.89; 95% CI, 0.81-0.98). There were no associations between GLP-1 RA use and outcomes in patients with cirrhosis. Conclusions and Relevance: In this cohort study, GLP-1 RA use was associated with a lower risk of progression to cirrhosis and mortality among patients with MASLD and diabetes. The protective association was not seen in patients with existing cirrhosis, underscoring the importance of treatment earlier in the disease course.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000520 · Cited by 3,476
Self-citationArmstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
A Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039
Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention
Huang, D. Q., El-Serag, H. B., & Loomba, R. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00381-6 · Cited by 1,855
Self-citationXiao, G., Zhu, S., Xiao, X., Yan, L., Yang, J., & Wu, G. (2017) · Hepatology · doi:10.1002/hep.29302 · Cited by 895
Harder, V. S., Stuart, E. A., & Anthony, J. C. (2010) · Psychological Methods · doi:10.1037/a0019623 · Cited by 802
Lund, J. L., Richardson, D. B., & Stürmer, T. (2015) · Current Epidemiology Reports · doi:10.1007/s40471-015-0053-5 · Cited by 739
Shi, Q., Nong, K., Vandvik, P. O., Guyatt, G. H., Schnell, O., Rydén, L., Marx, N., Brosius, F. C., Mustafa, R. A., Agarwal, A., et al. (2023) · BMJ · doi:10.1136/bmj-2022-074068 · Cited by 293
Diagnostic accuracy of noninvasive fibrosis models to detect change in fibrosis stage
Siddiqui, M. S., Yamada, G., Vuppalanchi, R., Van Natta, M., Loomba, R., Guy, C., Brandman, D., Tonascia, J., Chalasani, N., Neuschwander-Tetri, B., et al. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.12.031 · Cited by 272
Yan, J., Yao, B., Kuang, H., Yang, X., Huang, Q., Hong, T., Li, Y., Dou, J., Yang, W., Qin, G., et al. (2019) · Hepatology · doi:10.1002/hep.30320 · Cited by 260
Research works printed but not linked: 14
- Huang, 2022, Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer., Cell Metab, 34, 969, 10.1016/j.cmet.2022.05.003 · DOI · Paper page
- Wester, 2024, Glucagon-like peptide-1 receptor agonists and risk of major adverse liver outcomes in patients with chronic liver disease and type 2 diabetes., Gut, 73, 835, 10.1136/gutjnl-2023-330962 · DOI
- Lapham, 2012, Increased documented brief alcohol interventions with a performance measure and electronic decision support., Med Care, 50, 179, 10.1097/MLR.0b013e3181e35743 · DOI · Paper page
- Sohn, 2006, Accuracy and completeness of mortality data in the Department of Veterans Affairs., Popul Health Metr, 4, 2, 10.1186/1478-7954-4-2 · DOI · Paper page
- Hernán, 2016, Using big data to emulate a target trial when a randomized trial is not available., Am J Epidemiol, 183, 758, 10.1093/aje/kwv254 · DOI · Paper page
- Budd, 2020, Role of agents for the treatment of diabetes in the management of nonalcoholic fatty liver disease., Curr Diab Rep, 20, 59, 10.1007/s11892-020-01349-1 · DOI
- Mózes, 2022, Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis., Gut, 71, 1006, 10.1136/gutjnl-2021-324243 · DOI · Paper page
- Kanwal, 2012, The quality of care provided to patients with cirrhosis and ascites in the Department of Veterans Affairs., Gastroenterology, 143, 70, 10.1053/j.gastro.2012.03.038 · DOI
- Ruiz, 2018, Validation of an automatically generated screening score for frailty: the care assessment need (CAN) score., BMC Geriatr, 18, 106, 10.1186/s12877-018-0802-7 · DOI
- Ruiz, 2018, Association of the CAN score with the FRAIL scale in community dwelling older adults., Aging Clin Exp Res, 30, 1241, 10.1007/s40520-018-0910-4 · DOI
- Mahmud, 2022, The association between proton pump inhibitor exposure and key liver-related outcomes in patients with cirrhosis: a Veterans Affairs cohort study., Gastroenterology, 163, 257, 10.1053/j.gastro.2022.03.052 · DOI
- Wang, 2013, Predicting risk of hospitalization or death among patients receiving primary care in the Veterans Health Administration., Med Care, 51, 368, 10.1097/MLR.0b013e31827da95a · DOI · Paper page
- Tarao, 2019, Real impact of liver cirrhosis on the development of hepatocellular carcinoma in various liver diseases—meta-analytic assessment., Cancer Med, 8, 1054, 10.1002/cam4.1998 · DOI · Paper page
- Yen, 2024, Effects of glucagon-like peptide-1 receptor agonists on liver-related and cardiovascular mortality in patients with type 2 diabetes., BMC Med, 22, 8, 10.1186/s12916-023-03228-4 · DOI
Cited by
Cusi, K., Abdelmalek, M. F., Apovian, C. M., Balapattabi, K., Bannuru, R. R., Barb, D., Bardsley, J. K., Beverly, E. A., Corbin, K. D., ElSayed, N. A., et al. (2025) · Diabetes Care · doi:10.2337/dci24-0094 · Cited by 332
Self-citationMetabolic Dysfunction–Associated Steatotic Liver Disease
Targher, G., Valenti, L., & Byrne, C. D. (2025) · New England Journal of Medicine · doi:10.1056/nejmra2412865 · Cited by 325
Impact of GLP-1 Receptor Agonist Therapy in Patients High Risk for Sarcopenia
Memel, Z., Gold, S. L., Pearlman, M., Muratore, A., & Martindale, R. (2025) · Current Nutrition Reports · doi:10.1007/s13668-025-00649-w · Cited by 63
Hullon, D., Subeh, G. K., Volkova, Y., Janiec, K., Trach, A., & Mnevets, R. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02607-w · Cited by 59
Zafer, M., Tavaglione, F., Romero‐Gómez, M., & Loomba, R. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70196 · Cited by 47
“Importantly, recently published retrospective cohort studies using healthcare databases have suggested a potential beneficial effect of GLP-1 receptor agonists on long-term adverse liver outcomes, including cirrhosis, hepatic decompensation, and hepatocellular carcinoma [19, 20].”
Metadata
- Authors
- Kanwal, F., Kramer, J. R., Li, L., Yang, Y.-X., Cao, Y., Yu, X., Samuel, R., Ali, B., Desiderio, R., Cholankeril, G., Bajaj, M., El-Serag, H. B., & Asch, S. M.
- Venue
- JAMA Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2024-11-01
- Volume
- 184
- Issue
- 11
- Pages
- 1314
- ISSN
- 2168-6106 (ISSN-L)
- OpenAlex
- W4402581625
- Cited by
- 156
- References
- 14
- FWCI
- 40.79
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease. https://app.cochat.ai/papers/10.1001/jamainternmed.2024.4661
- The paper
- Kanwal, F., Kramer, J. R., Li, L., Yang, Y.-X., Cao, Y., Yu, X., Samuel, R., Ali, B., Desiderio, R., Cholankeril, G., Bajaj, M., El-Serag, H. B., & Asch, S. M. (2024). GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease. JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2024.4661
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.